U.S. biopharmaceutical company Viatris (NASDAQ: VTRS) and its partner, Indian biopharma Biocon, announced on July 28 that the U.S. Food and Drug Administration (FDA) had approved their biosimilar insulin drug, Semglee, as an “interchangeable biosimilar” — a direct alternative to Sanofi‘s (NASDAQ: SNY) blockbuster insulin drug, Lantus.